We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

New York Genome Institute Selects Exemplar LIMS to Manage Next Gen Sequencing Labs

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Exemplar LIMS™ has been selected as the primary lab management and electronic lab notebook (ELN) solution for NY Genome Center's laboratory operations.  Sapio's LIMS system will initially track next generation sequencing workflows from the Illumina family of sequencers from request through analysis.   Support for additional next gen sequencers will be added as needed.

Sapio's LIMS software will be deployed on Apple iPads™ using Exemplar LIMS for Tablets solution.  This enables lab technicians to take the LIMS with them as they move around the laboratory, improving LIMS usability and lab technician efficiency.    NY Genome Center will also be utilizing Exemplar's Materials Management capabilities for detailed tracking of reagent usage.  NYGC will ultimately be processing samples for both research and clinical applications via a CLIA certified laboratory.  Sapio's experience with implementing best practices for both research and clinical labs will accelerate the LIMS implementation in support of these NYGC objectives.

"The team at New York Genome Center has been impressed with the flexibility and scalability of Sapio's offerings," commented NYGC President & Scientific Director Robert B. Darnell, MD, PhD. "With Sapio we found an entrepreneurial partner that understands how important customer service and collaboration are to NYGC. We look forward to working with Sapio to design a solution for the genome center of the future."

 "The leadership at NYGC has recognized the importance of next generation sequencing technology for both research and clinical applications and has assembled a top-notch team from top to bottom.  We are both honored and enthused to be supporting the NYGC objectives with the ultimate goal of curing diseases," said Kevin Cramer, VP at Sapio Sciences. "We look forward to working with the NYGC team towards creating a world-class lab operation as they scale to be one of the largest NGS facilities in the North America."